|
1
|
Zhang J, Yang Y, Liu Y, Fan Y, Liu Z, Wang
X, Yuan Q, Yin Y, Yu J, Zhu M, et al: MicroRNA-21 regulates
biological behaviors in papillary thyroid carcinoma by targeting
programmed cell death 4. J Surg Res. 189:68–74. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Grant CS: Recurrence of papillary thyroid
cancer after optimized surgery. Gland Surg. 4:52–62.
2015.PubMed/NCBI
|
|
4
|
Srivastava A, Goldberger H, Dimtchev A,
Ramalinga M, Chijioke J, Marian C, Oermann EK, Uhm S, Kim JS, Chen
LN, et al: MicroRNA profiling in prostate cancer-the diagnostic
potential of urinary miR-205 and miR-214. PloS One. 8:e769942013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hodge LS, Elsawa SF, Grote DM,
Price-Troska TL, Asmann YW, Fonseca R, Gertz MA, Witzig TE, Novak
AJ and Ansell SM: MicroRNA expression in tumor cells from
Waldenstrom's macroglobulinemia reflects both their normal and
malignant cell counterparts. Blood Cancer J. 1:e242011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Adeniran AJ, Zhu Z, Gandhi M, Steward DL,
Fidler JP, Giordano TJ, Biddinger PW and Nikiforov YE: Correlation
between genetic alterations and microscopic features, clinical
manifestations and prognostic characteristics of thyroid papillary
carcinomas. Am J Surg Pathol. 30:216–222. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Espinosa AV, Porchia L and Ringel MD:
Targeting BRAF in thyroid cancer. Br J Cancer. 96:16–20. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pelizzo MR, Boschin IM, Barollo S,
Pennelli G, Toniato A, Zambonin L, Vianello F, Piotto A, Ide EC,
Pagetta C, et al: BRAF analysis by fine needle aspiration biopsy of
thyroid nodules improves preoperative identification of papillary
thyroid carcinoma and represents a prognostic factor. A
mono-institutional experience. Clin Chem Lab Med. 49:325–329. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ye WC, Gao L, Huang J, Fang XM and Xie G:
Suppressed Kruppellike factor 17 expression induces tumor
proliferation, metastasis and a poor prognosis in papillary thyroid
carcinoma. Mol Med Rep. 2014. View Article : Google Scholar
|
|
10
|
Pennelli G, Fassan M, Mian C, Pizzi M,
Balistreri M, Barollo S, Galuppini F, Guzzardo V, Pelizzo M and
Rugge M: PDCD4 expression in thyroid neoplasia. Virchows Arch.
462:95–100. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Peng Y, Li C, Luo DC, Ding JW, Zhang W and
Pan G: Expression profile and clinical significance of microRNAs in
papillary thyroid carcinoma. Molecules. 19:11586–11599. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pita JM, Banito A, Cavaco BM and Leite V:
Gene expression profiling associated with the progression to poorly
differentiated thyroid carcinomas. Br J Cancer. 101:1782–1791.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gautier L, Cope L, Bolstad BM and Irizarry
RA: affy-analysis of Affymetrix GeneChip data at the probe level.
Bioinformatics. 20:307–315. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Smyth GK: Limma: Linear models for
microarray data. Bioinformatics and Computational Biology Solutions
Using {R} and Bioconductor. Gentleman R, Carey VJ, Huber W,
Irizarry RA and Dudoit S: (New York). Springer. 397–420. 2005.
View Article : Google Scholar
|
|
15
|
Benjamini Y and Hochberg Y: Controlling
the false discovery rate: A practical and powerful approach to
multiple testing. J R Statist Soc B. 57:289–300. 1995.
|
|
16
|
Hulsegge I, Kommadath A and Smits MA:
Globaltest and GOEAST: Two different approaches for gene ontology
analysis. BMC Proc. 3(Suppl 4): S102009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ogata H, Goto S, Sato K, Fujibuchi W, Bono
H and Kanehisa M: KEGG: Kyoto encyclopedia of genes and genomes.
Nucleic Acids Res. 27:29–34. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dennis G Jr, Sherman BT, Hosack DA, Yang
J, Gao W, Lane HC and Lempicki RA: DAVID: Database for annotation,
visualization and integrated discovery. Genome Biol. 4:P32003.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rappaport N, Nativ N, Stelzer G, Twik M,
Guan-Golan Y, Stein TI, Bahir I, Belinky F, Morrey CP, Safran M and
Lancet D: Mala Cards: An integrated compendium for diseases and
their annotation. Database (Oxford). 2013:bat0182013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Franceschini A, Szklarczyk D, Frankild S,
Kuhn M, Simonovic M, Roth A, Lin J, Minguez P, Bork P, von Mering C
and Jensen LJ: STRING v9.1: Protein-protein interaction networks,
with increased coverage and integration. Nucleic Acids Res.
41:D808–D815. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Szklarczyk D, Franceschini A, Kuhn M,
Simonovic M, Roth A, Minguez P, Doerks T, Stark M, Muller J, Bork
P, et al: The STRING database in 2011: Functional interaction
networks of proteins, globally integrated and scored. Nucleic Acids
Res. 39:D561–D568. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Morris JH, Apeltsin L, Newman AM, Baumbach
J, Wittkop T, Su G, Bader GD and Ferrin TE: ClusterMaker: A
multi-algorithm clustering plugin for Cytoscape. BMC
Bioinformatics. 12:4362011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Enright AJ, Van Dongen S and Ouzounis CA:
An efficient algorithm for large-scale detection of protein
families. Nucleic Acids Res. 30:1575–1584. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Maere S, Heymans K and Kuiper M: BiNGO: A
Cytoscape plugin to assess overrepresentation of gene ontology
categories in biological networks. Bioinformatics. 21:3448–3449.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang J, Duncan D, Shi Z and Zhang B:
WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): Update 2013.
Nucleic Acids Res. 41:W77–W83. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen AY, Jemal A and Ward EM: Increasing
incidence of differentiated thyroid cancer in the United States,
1988–2005. Cancer. 115:3801–3807. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang C and Crapo LM: The epidemiology of
thyroid disease and implications for screening. Endocrinol Metab
Clin North Am. 26:189–218. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Breen EC and Tang K: Calcyclin
(S100A6) regulates pulmonary fibroblast proliferation,
morphology and cytoskeletal organization in vitro. J Cell Biochem.
88:848–854. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tsoporis JN, Izhar S and Parker TG:
Expression of S100A6 in cardiac myocytes limits apoptosis
induced by tumor necrosis factor-alpha. J Biol Chem.
283:30174–30183. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cross SS, Hamdy FC, Deloulme JC and Rehman
I: Expression of S100 proteins in normal human tissues and common
cancers using tissue microarrays: S100A6, S100A8, S100A9 and
S100A11 are all overexpressed in common cancers. Histopathology.
46:256–269. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ito Y, Yoshida H, Tomoda C, Uruno T, Miya
A, Kobayashi K, Matsuzuka F, Kakudo K, Kuma K and Miyauchi A:
Expression of S100A2 and S100A6 in thyroid carcinomas.
Histopathology. 46:569–575. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li Z, Tang M, Ling B, Liu S, Zheng Y, Nie
C, Yuan Z, Zhou L, Guo G, Tong A and Wei Y: Increased expression of
S100A6 promotes cell proliferation and migration in human
hepatocellular carcinoma. J Mol Med (Berl). 92:291–303. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Komatsu K, Kobune-Fujiwara Y, Andoh A,
Ishiguro S, Hunai H, Suzuki N, Kameyama M, Murata K, Miyoshi J,
Akedo H, et al: Increased expression of S100A6 at the
invading fronts of the primary lesion and liver metastasis in
patients witholorectal adenocarcinoma. Br J Cancer. 83:7692000.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ito Y, Yoshida H, Tomoda C, Uruno T, Miya
A, Kobayashi K, Matsuzuka F, Kakudo K, Kuma K and Miyauchi A:
Expression of S100A2 and S100A6 in thyroid carcinomas.
Histopathology. 46:569–575. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sofiadis A, Dinets A, Orre LM, Branca RM,
Juhlin CC, Foukakis T, Wallin G, Höög A, Hulchiy M, Zedenius J, et
al: Proteomic study of thyroid tumors reveals frequent
up-regulation of the Ca2+-binding protein S100A6 in
papillary thyroid carcinoma. Thyroid. 20:1067–1076. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pita JM, Figueiredo IF, Moura MM, Leite V
and Cavaco BM: Cell cycle deregulation and TP53 and RAS mutations
are major events in poorly differentiated and undifferentiated
thyroid carcinomas. J Clin Endocrinol Metab. 99:E497–E507.
2014.PubMed/NCBI
|
|
38
|
Quiros RM, Ding HG, Gattuso P, Prinz RA
and Xu X: Evidence that one subset of anaplastic thyroid carcinomas
are derived from papillary carcinomas due to BRAF and p53
mutations. Cancer. 103:2261–2268. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Naldini L, Vigna E, Narsimhan RP, Gaudino
G, Zarnegar R, Michalopoulos GK and Comoglio PM: Hepatocyte growth
factor (HGF) stimulates the tyrosine kinase activity of the
receptor encoded by the proto-oncogene c-MET. Oncogene. 6:501–504.
1991.PubMed/NCBI
|
|
40
|
Schmidt L, Junker K, Weirich G, Glenn G,
Choyke P, Lubensky I, Zhuang Z, Jeffers M, Van de Woude G, Neumann
H, et al: Two North American families with hereditary papillary
renal carcinoma and identical novel mutations in the MET
proto-oncogene. Cancer Rre. 58:1719–1722. 1998.
|
|
41
|
Rong S, Donehower LA, Hansen MF, Strong L,
Tainsky M, Jeffers M, Resau JH, Hudson E, Tsarfaty I and Van de
Woude GF: Met proto-oncogene product is overexpressed in tumors of
p53-deficient mice and tumors of Li-Fraumeni patients. Cancer Res.
55:1963–1970. 1995.PubMed/NCBI
|
|
42
|
Fujita S and Sugano K: Expression of c-met
proto-oncogene in primary colorectal cancer and liver metastases.
Jpn J Clin Oncol. 27:378–383. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Di Renzo M, Olivero M, Ferro S, Prat M,
Bongarzone I, Pilotti S, Belfiore A, Costantino A, Vigneri R,
Pierotti MA, et al: Overexpression of the c-MET/HGF receptor gene
in human thyroid carcinomas. Oncogene. 7:2549–2553. 1992.PubMed/NCBI
|
|
44
|
Di Renzo MF, Olivero M, Katsaros D,
Crepaldi T, Gaglia P, Zola P, Sismondi P and Comoglio PM:
Overexpression of the Met/HGF receptor in ovarian cancer. Int J
Cancer. 58:658–662. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Soejima H, Nakagawachi T, Zhao W,
Higashimoto K, Urano T, Matsukura S, Kitajima Y, Takeuchi M,
Nakayama M, Oshimura M, et al: Silencing of imprinted CDKN1C gene
expression is associated with loss of CpG and histone H3 lysine 9
methylation at DMR-LIT1 in esophageal cancer. Oncogene.
23:4380–4388. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hoffmann MJ, Florl AR, Seifert HH and
Schulz WA: Multiple mechanisms downregulate CDKN1C in human bladder
cancer. Internat J Cancer. 114:406–413. 2005. View Article : Google Scholar
|
|
47
|
Larson PS, Schlechter BL, King CL, Yang Q,
Glass CN, Mack C, Pistey R, de Las Morenas A and Rosenberg CL:
CDKN1C/p57kip2 is a candidate tumor suppressor gene in human breast
cancer. BMC Cancer. 8:682008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Algar EM, Muscat A, Dagar V, Rickert C,
Chow CW, Biegel JA, Ekert PG, Saffery R, Craig J, Johnstone RW and
Ashley DM: Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor
and activated by restoration of SMARCB1 and histone deacetylase
inhibitors. PLoS One. 4:e44822009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Tetzlaff MT, Liu A, Xu X, Master SR,
Baldwin DA, Tobias JW, Livolsi VA and Baloch ZW: Differential
expression of miRNAs in papillary thyroid carcinoma compared to
multinodular goiter using formalin fixed paraffin embedded tissues.
Endocr Pathol. 18:163–173. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Fornari F, Gramantieri L, Ferracin M,
Veronese A, Sabbioni S, Calin GA, Grazi GL, Giovannini C, Croce CM,
Bolondi L and Negrini M: MiR-221 controls CDKN1C/p57 and CDKN1B/p27
expression in human hepatocellular carcinoma. Oncogene.
27:5651–5661. 2008. View Article : Google Scholar : PubMed/NCBI
|
